Market adoption of Meridian Bioscience’s (NASDAQ:VIVO) new molecular diagnostic testing platform illumigene will go a long way toward determining the company’s future.Cincinnati-area Meridian is betting big on the technology, hoping it’ll help rescue the diagnostic testing company from its recent struggles. The company has reported declining year-over-year earnings in several recent quarters and twice in [...]

More bad news for investors in diagnostic testing company Meridian Bioscience (NASDAQ:VIVO).The Cincinnati-area company now projects its full-year results to come in at the “lower end” of a range of 68 cents to 71 cents per share, according to a statement. The news comes after Meridian last month pushed its guidance down from its previous [...]

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe.C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In recent years, C. difficile infections have become more frequent, more severe and more difficult to treat, [...]

Diagnostic testing company Meridian Bioscience (Nasdaq: VIVO) saw its shares fall as much as 13 percent in early trading Thursday, as the company downwardly revised its full-year earnings outlook.Shares of Meridian, whose tests can help doctors detect c. diff infection symptoms, were hovering around $23.87 in late-morning trading, after closing at $27.32 the prior day.In [...]

Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received U.S. Food and Drug Administration clearance for a new C. difficile test.C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In recent years, C. difficile infections have become more frequent, more severe and more difficult [...]

MedCity News’ Brandon Glenn breaks down the recent FDA approval of Meridian Bioscience’s pediatric version of its C. difficile test on this week’s edition of Health Journal on ONN.Meridian said its new product is the only C. difficile test that the U.S. Food and Drug Administration has cleared for use on children under the age [...]

Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received federal regulatory clearance to begin selling a pediatric version of its C. difficile test. An earlier version of the test, which the company calls the “illumigene,” was cleared for commercialization by the FDA in July. However, that clearance didn’t apply to children.

Life science diagnostic testing company Meridian Bioscience had a strong 2010 as swine flu fears pushed up demand for its rapid flu tests. But without swine flu, Meridian announced a 32 percent decrease in the diagnostic test maker’s first-quarter earnings for fiscal 2011.

It happened to diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO), but at least it doesn’t appear to have caused any damage. Meridian was victimized by a Twitter “name squatter.” That is, someone not affiliated with the company created a Twitter account using its name, logo and references to its website.

Diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO) capped a “disappointing” fiscal 2010 with fourth-quarter profits that fell below Wall Street’s expectations and sent its shares tumbling.